Navigation Links
VIVUS to Present at the Credit Suisse 2011 Healthcare Conference
Date:11/3/2011

MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Credit Suisse 2011 Healthcare Conference.

The VIVUS presentation will take place at the Arizona Biltmore Hotel in Phoenix, AZ on Thursday, November 10, 2011 at 9:30 a.m. MST.  A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial Qnexa NDA on October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction, with an FDA action date of April 29, 2012. For more information about the company, please visit www.vivus.com.

 CONTACT: 

  

 

 VIVUS, Inc. Investor Relations:The Trout Group 

 

 Timothy E. Morris 

Brian KorbChief Financial Officer 

bkorb@troutgroup.com 

 

 650-934-52 

646-378-2923   
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. VIVUS Resubmits Qnexa NDA to the FDA
2. VIVUS Provides Regulatory Update on QNEXA
3. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
4. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
5. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
6. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
7. VIVUS to Present at Three Upcoming Investor Conferences in March
8. VIVUS Provides Regulatory Update on QNEXA NDA
9. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
10. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
11. VIVUS to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
(Date:9/5/2017)... Sept. 5, 2017 Sapheneia and Scannerside received ... Scannerside DoseCheck is a third-party Vendor neutral CT product ... and allows compliance with current MITA standards. ... 29 DoseCheck solution is specifically designed to provide CT ... potential radiation doses over a predefined threshold. Scannerside Dose ...
Breaking Medicine Technology:
(Date:9/22/2017)... CA (PRWEB) , ... September 22, 2017 , ... ... to help you brush more effectively even on the go. Their electric toothbrushes ... gingivitis and gum inflammation, with UV sanitizing technology. Combining leading edge Enke technology ...
(Date:9/22/2017)... ... September 22, 2017 , ... Global ... diseases through research, education and awareness, today announced the appointment of Timothy J. ... microbiologist, Dr. Sellati has more than 20 years of research experience with Lyme ...
(Date:9/21/2017)... ... September 21, 2017 , ... The American Addiction Treatment Association ... professionals in the addiction treatment industry entitled: Special Investigations Unit (SIU) – ... and state and federal governments are increasingly scrutinizing the addiction treatment industry for ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... exercise more try taking a more holistic approach and use natural alternatives for ... essential oil collection is certified USDA guaranteeing that, the new line of essential ...
(Date:9/21/2017)... ... September 21, 2017 , ... A ... addiction recovery at a time when Virginia faces an opioid epidemic. ... a staggering increase of 38 percent from 2015, underscoring the need for additional ...
Breaking Medicine News(10 mins):